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Abstract
Background: The treatment for Plasmodium falciparum malaria in Sudan has been in process of
change since 2003. Preceding the change, this study aimed to determine which artemisinin-based
combination therapies is more effective to treat uncomplicated malaria in Malakal, Upper Nile,
Sudan.
Methods: Clinical trial to assess the efficacy of 2 antimalarial therapies to treat P. falciparum
infections in children aged 6–59 months, in a period of 42 days after treatment.
Results: A total of 269 children were followed up to 42 days. Artesunate plus Sulfadoxine/
Pyrimethamine (AS+SP) and Artesunate plus Amodiaquine (AS+AQ) were both found to be
efficacious in curing malaria infections by rapid elimination of parasites and clearance of fever, in
preventing recrudescence and suppressing gametocytaemia. The combination of AS+SP appeared
slightly more efficacious than AS+AQ, with 4.4% (4/116) versus 15% (17/113) of patients returning
with malaria during the 6-week period after treatment (RR = 0.9, 95% CI 0.81–0.96). PCR analysis
identified only one recrudescence which, together with one other early treatment failure, gave
efficacy rates of 99.0% for AS+AQ (96/97) and 99.1% for AS+SP (112/113). However, PCR results
were incomplete and assuming part of the indeterminate samples were recrudescent infections
leads to an estimated efficacy ranging 97–98% for AS+SP and 88–95% for AS+AQ.
Conclusion: These results lead to the recommendation of ACT, and specifically AS+SP, for the
treatment of uncomplicated falciparum malaria in this area of Sudan. When implemented, ACT
efficacy should be monitored in sentinel sites representing different areas of the country.
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Introduction
The health situation in Sudan continues to be affected by
long-lasting conflict and related humanitarian emergen-
cies such as food crises and epidemics. Malaria is one of
the major causes of morbidity and mortality. In Sudan, an
estimated 7.5 million patients suffer from malaria each
year and 35,000 die from this disease, which accounts for
up to 20% of hospital deaths [1]. The problem appears to
have worsened in recent years due to increasing levels of
Plasmodium falciparum resistance against the two most
commonly used antimalarials: chloroquine (CQ) and sul-
fadoxine/pyrimethamine (SP). CQ resistance in the
northern and central part of the Sudan is near 50% [2]. In
the South, CQ resistance below 15% was found in some
isolated locations [3,4], but was over 80% elsewhere [5,6].
Resistance to SP was shown by presence of SP-resistant
genotypes [7] and in vivo studies documenting of 0–11%
resistance in Khartoum and the eastern part of the country
[2,8] and varying levels of 0, 16% up to 70% in different
locations in the southern part of the country [4-6]. Amo-
diaquine (AQ) provided an alternative for CQ in Africa in
recent years; this drug is not officially registered in the
Sudan, and due to its limited use, was expected to have
preserved good efficacy.
The nationally recommended treatment protocol for P.
falciparum malaria in Sudan at the time of this study was
still CQ as first-line and SP as second-line. A change in
protocol was however in progress, and the Sudanese
Health authorities had indicated that artemisinin-based
combination therapy (ACT) was the preferred new first-
line treatment [9]. The World Health Organization
(WHO), MSF and various other NGOs supported this
viewpoint [10,11].
In line with recommendations for several other African
countries, two ACTs were proposed for Sudan: Artesunate
(AS) +SP or AS+AQ. The third option, used in other Afri-
can countries, Artemether-Lumefantrine (Coartem) was
not seen as a viable option at the time, because of its cost.
To provide information on the efficacy of ACT treatment
in Sudan, the in vivo therapeutic efficacy of the first two
combinations were studied in Malakal town, Upper Nile
State.
Patients and Methods
Malakal is located in southern Sudan (on the edge of the
Khartoum-governed area), which is an area is of medium
to high malaria endemicity (main transmission season:
June-November). This open-label study was done in
Malakal paediatric hospital supported by Médecins Sans
Frontières, from September 2003 to January 2004. The
methodology used was in accordance with standard WHO
procedures for antimalarial drug efficacy assessment in
high transmission settings [12,13]. Children aged
between 6 months and 5 years with fever (axillary temper-
ature of 37.5°C or more) and P. falciparum infection with
a density of 2,000 to 200,000 parasites/µl but no signs of
severe malaria (WHO criteria, [13]) or any other serious
health condition were included in the study (provided
written parental consent was given). One of the two ther-
apies was allocated (by sequential alternation), and given
under supervision: either (1) AS+SP, 3 days AS 4 mg/kg
body weight on day 0, 1 and 2 plus SP, 25/1.25 mg/kg,
single dose on day 0 or (2) AS+AQ, 3 days AS 4 mg/kg on
day 0, 1 and 2 plus AQ 10 mg/kg on day 0, 1, 2. Doses
were calculated for weight categories in quarter tablets. In
case of vomiting within 30 minutes, the treatment was
repeated. Repeated vomiting led to exclusion from study
and referral to the hospital for quinine treatment. Medica-
tions were normally given in the mornings and appoint-
ments for next day roughly matched 24 hr intervals.
Artesunate was obtained from Dafra (Belgium) and SP
and AQ from IDA (the Netherlands).
The sample size of at least 116 inclusions per arm was cal-
culated to detect a 12% difference between the two arms,
assuming a 97% efficacy at day 28 for the AS+SP arm
(based on 100% efficacy of SP found in a recent study per-
formed at a nearby location, [4]) and 85% for the AS+AQ
arm (internationally recommended level for change),
with 80% power and 5% risk type I error, anticipating a
loss to follow-up of 10%. Patients returned daily during
the first 3 days of illness and weekly thereafter for 6 weeks
(42 days) after treatment. Side effects of drugs and self-
medication were recorded based on patient reports and
actively asked for during visits. Cases which remained
negative during follow-up were considered Adequate
Clinical and Parasitological Responses (ACPR). Failures
were classified as (1) Early Treatment Failures (ETF) in
case of significant parasitaemia at day 2 or 3 or parasites
and fever at day 3, (2) Late Clinical Failures (LCF) for
cases with parasites and fever during follow-up after day 3
and (3) Late Parasitological Failures (LPF) for parasite
infections without fever at day 42, all in accordance with
WHO guidelines [13]. Rescue treatment for failures was
quinine 10 mg/kg/eight-hourly for 7 days. PCR analysis
was used to distinguish new infections from
recrudescences.
Slides were examined by two microscopists independ-
ently and 20% of slides were cross-checked in an external
laboratory (at KEMRI, Nairobi). The density of parasites
was determined by simultaneous count of white blood
cells and parasites, assuming a standard density of 8,000
WBCs per µl [13]. Haemoglobin levels were evaluated at
day 0, 14, 28 and 42, to observe return to healthy Hb-lev-
els after effective antimalarial treatment. PCR analysis of
the msp1 and msp2 loci was used to distinguish re-infec-
tions from recrudescences [14,15]. In case of two or more
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identical alleles in pre- and post-treatment genotypes, the
case was classified as recrudescent, or as a new infection if
one or none of the alleles matched. Cases were excluded
from the final analysis in case of loss to follow-up, self-
medication with antimalarials and concomitant disease
and when PCR results showed re-infections or were unde-
termined due to missing samples, undetermined geno-
types or non-amplifiable DNA.
The research protocol was reviewed and approved by the
Sudan Research Directorate, the Malaria, Leishmaniasis
and Schistosomiasis Directorate, as well as by the Ethical
Review Board of MSF (comprising of MSF-external experts
only). During recruitment of the children in study,
informed written consent was obtained from their
parents/guardians.
Results
A total of 269 children were recruited during the 5-month
study period. Of these, 134 were treated with AS+AQ and
135 with AS+SP. Baseline characteristics were similar in
both treatment groups (Table 1). Of the children
included, 40 were excluded from the final analysis due to
associated serious other febrile illness (n = 15), self-med-
ication with antimalarials (n = 7), loss to follow-up (n =
13) or erroneous inclusion/classification (n = 5, i.e. three
cases of disagreement over microscopy quality control,
two cases retreated with parasites but no fever prior to day
42 in AS+AQ group). There were three children with Hb
level of 5.0 g/dl included (limit of in/exclusion), based on
their condition assessed by the medical doctor. Alto-
gether, 113 (84%) completed the study after treatment
with AS+AQ and 116 (86%) with AS+SP (Figure 1).
Table 1: Baseline characteristics of patients at study-enrolment, per treatment arm, Malakal, Upper Nile, Sudan 2003–4.
AS + AQ (n = 134) AS + SP (n = 135)
Sex ratio (F/M) 68/66 64/71
Mean age (months) (SD, ranges) 33 (13, 7–59) 33 (15, 6–59)
Mean weight (kg) (SD, ranges) 11.1 (2.4, 5.7–17.0) 11.3 (2.6, 5.4–18.0)
Mean axillary temperature (°C) (SD, ranges) 38.7 (0.9, 37.5–40.9) 38.9 (0.9, 37.5–40.9)
Mean haemoglobin value (g/dl) (SD, ranges) 7.8 (1.7, 5.0–12.2) 7.9 (1.8, 5.0–12.7)
Parasitaemia geometric mean (/µl) (ranges) 20 952 (2 100–199 500) 24835 (2 000–198 000)
Table 2: Treatment endpoints on day 28, 42 after treatment and PCR adjusted day 42, Malakal, Upper Nile, Sudan, 2003–2004
AS + AQ AS + SP
N % 95% CI N % 95% CI
Day 28 Results 117 116
ACPR 105 89.7 82.8–94.6 114 98.3 93.9 – 99.8
ETF 0 0 1 0.9 0.0–4.7
LCF 10 8.5 4.2–15.2 1 0.9 0.0–4.7
LPF 2 1.7 0.2–6.0 0 0
Day 42 Results 113 116
ACPR 96 85.0 77.0–91.0 112 96.6 91.4–99.1
ETF 0 0 1 0.9 0.0–4.7
LCF 15 13.3 7.6–20.9 2 1.7 0.2–6.1
LPF 2 1.8 0.2–6.2 1 0.9 0.0–4.7
PCR corrected day 42# 97 113
No PCR result (12) (2)
Re-infections (4) (1)
ACPR 96 99.0 94.4–100 112 99.1 95.2–100
ETF 0 0 0.0–3.7 1 0.9 0.0–4.8
LCF 1 1.0 0.0–5.6 0 0 0.0–3.2
LPF 0 0 0.0–3.7 0 0 0.0–3.2
#Cases with missing or undetermined PCR results and re-infections were excluded from the analysis. ACPR = Adequate Clinical Parasitological 
Response, ETF = Early Treatment Failure, LCF = Late Clinical Failure, LPF = Late Parasitological Failure.
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Both artemisinin-combitherapies were highly effective to
treat P. falciparum infections and prevent parasite re-emer-
gence. Only 1 case of ETF was found, in the AS+SP group
(Table 2). At day 28 and day 42, the proportion of patients
still parasite-free was higher in the group treated with
AS+SP than in the group AS +AQ (χ2 test, p = 0.014 for
results day 28; p = 0.0049 for day 42).
PCR analysis was unable to generate results for a large part
of cases (only 6/20 available, Figure 1). In the AS+AQ
treatment group, of 17 failures, only 1 was confirmed to
be recrudescent, whereas of the other cases, 4 were re-
infections and 12 samples were not analyzable. Of the 3
'failures' in the AS + SP group, one was an early treatment
failure, PCR identified 1 re-infection and 2 were non-ana-
lysable. Hence, with the PCR correction and exclusions of
non-analysable and re-infection cases, AS+AQ resulted in
1.0% confirmed failures (1/97) and AS+SP in 0.9% true
failures (1/113) (Table 2). Extrapolation of the cases with
known PCR results to the ones that remained undeter-
mined (assuming 2/3 of parasitemia due to reinfection),
would give a 95.3% efficacy of AS+AQ (101/106) and
98.2% of AS+SP (112/114). Alternatively, a 'worst case'
scenario, assuming that all non-analysable PCRs were
actually recrudescences, would lead to 88.1% efficacy in
the AS+AQ group (96/109) and 97.4% for AS+SP (111/
114).
Parasites were rapidly cleared in both treatment groups. At
day 2 only 17% and 22% of patients still had a (low) par-
asitaemia in the AS+AQ and AS+SP groups, respectively.
Gametocytes were found in 20% (52/262) of children on
inclusion. During follow-up, 78% of these carriers at
enrolment showed gametocytes again on one or more fol-
low-up days (32/41), whereas 22% of the children with-
out gametocytes at inclusion were later found to be
gametocytemic (42/192). There was no difference
between the age, temperature, parasitemia, haemoglobin
on admission of the two groups, neither in rates of ACPR
at study-endpoint. Gametocyte carriage was similar in
both treatment groups and all gametocytes disappeared
gradually from the blood during the first weeks after fol-
low-up, and cleared by day 21 in 95% of cases (Figure 2).
The body temperature of all patients went down quickly;
fever clearance (T<37.5°C) at day 1 and day 2 was 86%
and 97% in the AS + AQ group and 83% and 93% in the
AS+SP, and at day 3 all but one (on AS+SP) were free from
fever. Average haemoglobin levels for the AS+AQ and
AS+SP treatment groups increased from under 8.0 g/dl to
near 10 g/dl 6 weeks after treatment. The proportion of
children classified as moderately anaemic (haemoglobin
from 5 to 8 g/dl) reduced from 51% to 11% during fol-
low-up period, similar in both arms. No serious adverse
events were observed or reported on routine clinical
Patient flow during recruitment and follow-upFigure 1
Patient flow during recruitment and follow-up
Total 269 study patients recruited
AS + SP
135 patients enrolled
AS+AQ
134 patients enrolled
117 patients analysable
16 lost/excluded
116 patients analysable113 patients analysable
Day 0
Day 28
Day 42
118 patients analysable
18 lost/excluded
5 lost/excluded 1 lost
PCR
12 PCR indetermined
4 Re-infections
2 PCR indetermined
1 Re-infection97 analysed 113 analysed
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examination during follow-up and none of the failures
developed complicated malaria.
Discussion
This is one of the first studies into the clinical outcomes of
ACT combination therapy in Sudan and provides useful
information for decision-makers working to ensure effec-
tive antimalarial protocols in this part of the country.
Both of the artemisinin-based combination therapies
tested here were found to be highly efficacious in the treat-
ment of uncomplicated P. falciparum malaria in this area
of the Sudan. AS+SP appears to be the better treatment
option on the basis of non-PCR corrected responses,
showing a lower percentage of patients returning with par-
asitaemia. The PCR analysis indicates the true efficacy is
comparable between both treatments (near 99%), but is,
however, limited by a high proportion of indeterminate
cases. More realistically, an efficacy between 97–98% can
be expected for AS+SP and 88–95% for AS+AQ, accepta-
ble levels after the long follow-up of 42 days after treat-
ment. A rapid parasite clearance and fever reduction was
found following treatment with both ACTs. The rise in
haemoglobin values and the reduction of the proportion
of (moderately) anaemic children after treatment con-
firms that the malaria parasites were effectively removed
from the blood and red blood cell levels rose after
treatment.
The ACTs tested also had an effect on gametocytes. In gen-
eral, the gametocidal action of AS appears to work
through preventing the development of new gametocytes
rather than clearance of existing ones [16]. In our study,
the 20% of gametocyte-carrying infections at enrolment
cleared gradually by day 21. Newly detected gametocytes
developed in 22% of cases after treatment, which is lower
than after monotherapy, at least for SP. A previous study
in Upper Nile [4] showed that 68% of patients (of all
ages) treated with SP and 28% of those treated with AQ
developed gametocytaemia during the 14 days after treat-
Parasitaemia and gametocytaemia during 6-week follow-upFigure 2
Parasitaemia and gametocytaemia during 6-week follow-up. Symbols: AS+SP ▲ parasites  gametocytes, AS+AQ ●  parasites 
❍ gametocytes. Error bars indicate 95%CI.
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ment, while gametocyte prevalence at admission was only
2%. Gametocidal effect is very important since the sexual
stages of parasites are essential for person-to-person trans-
mission of malaria via mosquito vectors.
The main limitations of the study were that the number of
patient exclusions were higher than anticipated (15%)
due to concomitant febrile illnesses and loss to follow-up,
as well as the lack of results for PCR-analysis, caused by
samples missing or an inability to provide sufficient DNA
on amplification due to low densities in post-treatment
samples. Increasing the number of inclusions compen-
sated losses to follow-up. Repeated attempts at PCR-anal-
ysis for problematic samples were only partly successful
and, therefore, lead to extrapolation about the findings
for the missing samples.
At time of writing, a change of national protocols towards
ACT in northern Sudan is in preparation – coordinated
among health authorities, NGOs and other relevant
actors. The first line treatment recommended country-
wide is AS+SP, based on reported high efficacy of SP.
Northern Sudan is the only country in Africa, which has
chosen the option AS+SP [17]. On the basis of the results
of this study, this is justifiable. One other study in Sudan
on AS+SP and AS+AQ efficacy was recently completed in
the Nuba Mountains and also shows high efficacy of
91.2% and 92.7%, respectively, for these ACTs at 28 days
after treatment [18]. ACTs with SP or AQ as companion
drugs have shown to be very effective in other areas of
Africa, provided that the companion drug still maintained
a good level of efficacy [19-22]. In the Upper Nile area
both SP and AQ were still an effective treatment for P. fal-
ciparum and SP has shown high efficacy in various areas of
northern Sudan [2,4,23]. It remains to be seen whether
AS+SP will be equally efficacious in other, e.g. more
northern areas of the Sudan. In Southern Sudan AS+AQ
has recently been put forward as the therapy of choice
[17]. The use of two different therapies would seem a sen-
sible option in a vast country with areas of different pat-
terns of resistance.
An advantage of AS+SP over AS+AQ is that it is more con-
venient to administer, as SP is given as a single dose and
can be administered under observation in a health facility,
whereas AQ requires 3 days to complete a course. SP tab-
lets are also easier to take (AQ has a bitter taste). Blister
packs of AS+SP, which combine the two drugs and clearly
indicate daily tablets to be taken, are currently available
for different age categories in Sudan. AS+SP is cheaper
than AS+AQ.
Implementation of the new national protocol with AS+SP
will hopefully take place as quickly as possible to prevent
rising morbidity and mortality. Vulnerable displaced pop-
ulations in epidemic-prone areas and areas of high peren-
nial malaria transmission should be prioritized.
Introduction of ACT will have to go hand in hand with
laboratory confirmed diagnosis (microscopy or rapid
diagnostic tests) to prevent unnecessary use of valuable
drugs (thus minimizing drug pressure) and ensure that
non-malarial cases are appropriately treated. The change
in guidelines should also filter through all health service
providers, including the private sector and drug vendors
to decrease the potential risk of SP monotherapy and
incomplete dosages. The change will initially require
more funds to be made available for malaria treatment.
The international community – including many NGOs,
the WHO, donors, and the Global Fund – has shown will-
ingness to support countries to change antimalarial proto-
cols [24,25].
At present, MSF has already started to pilot AS+SP treat-
ment in its project areas in Northern Sudan, i.e. Darfur,
Upper Nile and Gedaref, on behalf of the Ministry of
Health. The implementation of treatment as well as the
future efficacy of AS+SP should be monitored carefully in
a number of dispersed sentinel sites, as there is a possibil-
ity that SP resistance may further rise before the combina-
tion has been made available countrywide.
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